Hormonal
Gut microbiota dysbiosis in women with Polycystic Ovary Syndrome (PCOS) is significantly associated with clinical phenotypes, including elevated testosterone, increased waist circumference, and altered brain-gut peptides (serotonin, ghrelin, PYY).
This research suggests that the gut health of women with PCOS differs from controls, specifically showing lower levels of beneficial bacteria (like Akkermansia) and higher levels of potentially inflammatory bacteria (like Escherichia/Shigella). These microbial differences are linked to higher testosterone and waist circumference. While this study does not prescribe a specific diet, it supports the investigation of dietary interventions aimed at improving gut microbiota diversity as a potential strategy to manage PCOS symptoms.
Here, we showed an altered gut microbiota significantly correlated with PCOS phenotype. There were 33 patients with PCOS... as well as 15 control subjects... The plasma levels of serotonin, ghrelin, and peptide YY (PYY) were significantly decreased in patients with PCOS compared with controls, and have a significantly negative correlation with waist circumference and testosterone.
Why this rating
Observational clinical study with a relatively small sample size (n=48) and cross-sectional design; establishes correlation but not causation.
Source
Dysbiosis of Gut Microbiota Associated with Clinical Parameters in Polycystic Ovary Syndrome
Rui Liu et al. · Frontiers in Microbiology · 2017
DOI 10.3389/fmicb.2017.00324
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →